肿瘤学领域的共同研究及授权契约:2020年～2025年

《肿瘤学合作与许可交易》提供了前所未有的途径，可以全面了解全球领先的生物製药公司正在进行的肿瘤学交易。

本报告提供了 2020 年至 2025 年 3,350 笔肿瘤学交易的详细资讯。

此报告提供双方宣布的交易的付款条款。这些数据为付款条款和其他贸易条款提供了有用的见解。

了解潜在合作伙伴谈判的交易条款的灵活性，可以为谈判过程提供重要的见解，让您了解在谈判条款时可以期望实现的目标。许多小型企业可能会想要详细的付款条款，但当涉及到如何产生付款以及如何转移权利时，细节决定成败。

本报告提供了当前协议交易和合作资料库中记录的自 2020 年以来宣布的合作和许可协议的综合清单。

报告的第一章介绍了肿瘤学领域的交易和商业活动。第 1 章对报告进行了介绍，第 2 章分析了肿瘤学领域的交易趋势。

第 3 章介绍了肿瘤学领域已达成交易的财务条款和发展阶段。交易按标题价值、预付款、里程碑和特许权使用费列出并分为几个部分。

第 4 章回顾了在肿瘤学交易中最活跃的 25 家生物製药公司。对于与美国证券交易委员会 (SEC) 公开宣布的协议交易，可以透过目前协议交易和联盟资料库中的连结在线存取这些协议。

第 5 章全面深入地回顾了 2020 年以来签署和宣布的肿瘤学交易，并提供合约文件。每个交易标题都透过网路连结连结到实际合约文件的线上版本，从而可以轻鬆根据需要存取每个合约文件。

第 6 章提供了按目标分类的肿瘤学病例综合目录。

该报告还包括大量图表和图形，重点介绍了 2020 年及以后的肿瘤学承包趋势和活动。

此外，我们的综合贸易目录按公司 A-Z 和技术类型进行组织。每个交易标题都包含一个指向在线交易记录的网络链接，以及（如果有）合同文件的网络链接，以便根据需要轻鬆访问每个文件。

主要优点

肿瘤学研究合作和授权协议为读者提供了以下主要好处：

• 了解 2020 年及以后的合约趋势
• 浏览肿瘤学合作与许可机会
• 基准分析 - 确定交易的市场价值
• 财务条款 – 预付款、里程碑付款、特许权使用费
• 依公司 A-Z、治疗目标、技术类型划分的交易目录
• 大额交易金额
• 最活跃的交易者
• 确定每笔交易的资产和条款
• 查阅合约文件－洞察交易结构
• 尽职调查 - 评估拟议交易条款对合作伙伴公司的适用性。
• 节省数百小时的研究时间

研究范围

• 肿瘤学研究合作与许可协议旨在从全球领先的生物製药公司更深入地了解肿瘤学趋势和交易结构。

回报内容

• 生物製药产业肿瘤学领域的交易趋势
• 合作与授权交易结构概述
• 涵盖製药和生物技术的肿瘤学交易记录目录
• 主要肿瘤学交易（各价值）
• 最活跃的肿瘤学许可交易促成者

目录

摘要整理

第1章 简介

第2章 肿瘤学领域的交易趋势

• 简介
• 多年的肿瘤学的联盟
• 各交易类型的肿瘤学领域的联盟
• 各业界的肿瘤学领域的联盟
• 各开发阶段的肿瘤学领域的联盟
• 各技术类型的肿瘤学领域的联盟
• 各治疗适应症的肿瘤学领域的联盟

第3章 肿瘤学领域的联盟的财务交易条件

• 简介
• 公开肿瘤学领域的联盟相关财务条件
• 肿瘤学领域的联盟的主要价值
• 肿瘤学领域的交易的预付款金
• 肿瘤学领域的交易的里程金
• 肿瘤学的权利金费率

第4章 -肿瘤学的主要交易和交易厂商

• 简介
• 在肿瘤学合作方面最活跃的公司
• 肿瘤学领域最活跃的交易者名单
• 顶级肿瘤学交易

第5章 肿瘤学契约文件名录

• 简介
• 已签约的肿瘤学合作协议

第6章 按治疗标的肿瘤学领域的交易

• 简介
• 按肿瘤治疗标的交易
• 交易名录
• 交易目录 - 2020 年至 2025 年肿瘤学交易（依公司划分）
• 交易目录 - 按技术类型划分的肿瘤学交易（2020-2025 年）
• 定义交易类型
• 关于 Biopharma Research Ltd
• 当前合作伙伴关係
• 当前合约
• Current Partnering 的最新报告标题

Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of 3,350 oncology deals from 2020 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in oncology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the oncology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in oncology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of oncology deals signed and announced since 2020 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of oncology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in oncology deal making since 2020.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse oncology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Oncology Collaboration and Licensing Deals includes:

• Trends in oncology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of oncology deal records covering pharmaceutical and biotechnology
• The leading oncology deals by value
• Most active oncology licensing dealmakers

In Oncology Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in oncology dealmaking

• 2.1. Introduction
• 2.2. Oncology partnering over the years
• 2.3. Oncology partnering by deal type
• 2.4. Oncology partnering by industry sector
• 2.5. Oncology partnering by stage of development
• 2.6. Oncology partnering by technology type
• 2.7. Oncology partnering by therapeutic indication

Chapter 3 - Financial deal terms for oncology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for oncology partnering
• 3.3. Oncology partnering headline values
• 3.4. Oncology deal upfront payments
• 3.5. Oncology deal milestone payments
• 3.6. Oncology royalty rates

Chapter 4 - Leading oncology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in oncology partnering
• 4.3. List of most active dealmakers in oncology
• 4.4. Top oncology deals by value

Chapter 5 - Oncology contract document directory

• 5.1. Introduction
• 5.2. Oncology partnering deals where contract document available

Chapter 6 - Oncology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by oncology therapeutic target
• Deal directory
• Deal directory - Oncology deals by company A-Z 2020 to 2025
• Deal directory - Oncology deals by technology type 2020 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Oncology partnering since 2020
• Figure 2: Oncology partnering by deal type since 2020
• Figure 3: Oncology partnering by industry sector since 2020
• Figure 4: Oncology partnering by stage of development since 2020
• Figure 5: Oncology partnering by technology type since 2020
• Figure 6: Oncology partnering by indication since 2020
• Figure 7: Oncology deals with a headline value
• Figure 8: Oncology deals with upfront payment values
• Figure 9: Oncology deals with milestone payment
• Figure 10: Oncology deals with royalty rates
• Figure 11: Active oncology dealmaking activity since 2020
• Figure 12: Top oncology deals by value since 2020